Author Archive: Jason Corum

Jason Corum

Jason is the director of web and new media with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.

Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation.  He spends his free time volunteering with the DC Books to Prisons Project, watching movies and reading comics.

Latest Posts

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

bluebird bio

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. Previously, he served as interim chief executive officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

BIO Investor Forum

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming the body’s own t-cells to have greater impact on reducing tumors and preventing the spread of disease. CAR-T methods that extract, reengineer, and reintroduce a given patient’s t-cells provide highly personalized therapy but may be difficult to scale up. The interleukin enhancement approach motivates existing t-cells to be more effective and may be easier to deliver but have less pervasive Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biotech Analyst Optimism: Price Targets Post-IPO

Stock Ticker

In a recent blog post, Bruce Booth of Life Sci VC, writes about the relationship between a forecasted price target of a biotech stock and its current share price. If biotech stocks hit their current targets, it could be a good year, Booth writes: “I’ll close with a thought experiment as an optimist: if, in line with historic data, 45% of the current IPO class hits their price targets at some point over the next Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

medicine-thumb

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how ObamaCare is already bending the future of U.S. medical progress, consult the furor over specialty drug prices, as an alliance of convenience among third-party payers assails pharmaceutical innovation as too costly. Maybe patients should give up on cures and, as President Obama once put it, just take the painkiller…” Read the full opinion

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Cancer Death-Panel App

Annie Cavanagh. Wellcome Images

In an article for the New York Post, Robert Goldberg, vice president of the Center for Medicine in the Public Interest, wrote about an app that will use an algorithm like those health plans apply to limit access to innovative treatments: “At ASCO’s national conference, Dr. Lee Newcomer, United Healthcare’s medical director, said the ‘motives [of insurers] are viewed with suspicion when it comes to deciding whether a treatment is cost-effective. So having ASCO play Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,